Global biopharmaceutical leaders continue to make significant strides in retinal disease treatments as Bayer, Regeneron and Roche are all rapidly increased its market share across wet AMD and DME.
Additionally, biotechs are pioneering new breakthroughs such as Outlook Therapeutics developing new drug approval for wet AMD, while Ocular Therapeutix progresses innovative sustained-release drug delivery systems to extend treatment intervals and enhance patient outcomes in retinal diseases.
The 2025 Wet AMD & Diabetic Eye Disease Drug Summit is the only industry-led event dedicated to exploring the latest advancements, strategic collaborations, and cutting-edge research driving the field of retinal disease treatment forward.
Join a dynamic community of 70+ global leaders, including translational, clinical, and commercial experts as they gather at this premier summit. Attendees will gain unparalleled insights into emerging therapies, adaptive trial designs, and the latest clinical studies aimed at improving treatment efficacy and patient care.
2025 Agenda Highlights:
Bayer: Showcasing the NEON-NPDR trial for runcaciguat, highlighting its potential to enhance retinal health by activating soluble guanylate cyclase and improving blood flow in NPDR
Sanofi: Presenting novel device innovations and refined dosing strategies aimed at streamlining retinal vascular treatment administration and enhancing patient adherence
Ocular Therapeutix: Introducing AXPAXLI (OTX-TKI), a sustained-release hydrogel implant promising extended treatment intervals for wet AMD and DR
Outlook Therapeutics: Highlighting the advancements of ONS-5010, a next-gen ophthalmology therapy designed for reliable, consistent care in retinal therapy
HuidaGene Therapeutics: Unveiling the first CRISPR/RNA-targeting therapy, HG202, developed to address neovascular AMD with innovative gene-editing technology
DOWNLOAD THE 2025 FULL EVENT GUIDE
World-Class Speaker Faculty Includes:
Previously Attending Companies Include:
Hear From Past Attendees:
“Close communications and networking opportunities with qualified individuals, and the latest R&D information.”
Hiroaki Serizawa, Chief Executive Officer, AMD Therapeutics
“The intimate very friendly setting allowed for a truly meaningful interactions between speakers and the audience”
Anna Frostegard, Chief Scientific & Medical Officer, Annexin Pharmaceuticals
“There were some really useful discussions and I was impressed with the quality of the agenda and content”
Peter Bloomfield, Director, Research, Macular Society
Other Events in the Ophthalmology & Sensory Series:
